

AD _____

Award Number: W81XWH-10-1-0341

TITLE: Genetic Modifiers of Ovarian Cancer

PRINCIPAL INVESTIGATOR: Fergus J. Couch, Ph.D.

CONTRACTING ORGANIZATION: Mayo Clinic
Rochester, MN 55905

REPORT DATE: June 2013

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) June 2013		2. REPORT TYPE Annual		3. DATES COVERED (From - To) 15 May 2012 - 14 May 2013	
4. TITLE AND SUBTITLE Genetic Modifiers of Ovarian Cancer				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-10-1-0341	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Fergus J. Couch, Ph.D. E-Mail: couch.fergus@mayo.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Mayo Clinic Rochester, MN 55905				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Individuals with germline mutations in BRCA1 have an elevated but incomplete risk of developing ovarian cancer suggesting the presence of genetic modifiers of ovarian cancer in this population. A genome wide association study (GWAS) for ovarian cancer in BRCA1 mutation carriers has identified several novel modifiers of ovarian cancer risk for BRCA1 mutation carriers that can be used for individualized ovarian cancer risk assessment.					
15. SUBJECT TERMS BRCA1, ovarian cancer, genome wide association study, association study					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	9	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	4
BODY.....	4-6
Key Research Accomplishments.....	6
Reportable Outcomes.....	6-9
Conclusion.....	9

Introduction:

Inactivating mutations in the *BRCA1* tumor suppressor gene have been detected in approximately 10% of all ovarian cancers. Individuals with germline mutations in *BRCA1* have a substantially increased risk of developing ovarian cancer as compared to the general population, with an estimated cumulative risk of ovarian cancer by age 70 of 39%. These findings indicate that although *BRCA1* mutation carriers are at high risk for developing ovarian cancer, a sizeable proportion of women who carry a deleterious mutation will not develop this disease. In addition, the findings show that there is considerable variation in the age of onset of ovarian cancer in this population. This variable penetrance and age of onset of ovarian cancer suggest that there are additional genetic and environmental factors that modify the age specific risk of ovarian cancer for *BRCA1* mutation carriers. Common genetic variants that are associated with the risk of ovarian cancer have recently been identified through candidate gene and genome wide association studies in the general population. This suggests that common genetic variants may also modify ovarian cancer risk in carriers of *BRCA1* mutations. Identification of these genetic risk factors may prove useful for identifying those *BRCA1* carriers at elevated or lowered risk of ovarian cancer compared to the average *BRCA1* carrier. Women at increased risk may subsequently benefit from enhanced screening or certain prevention measures such as prophylactic oophorectomy, whereas women at lowered risk may be able to avoid these types of intervention. Thus, we proposed a study aimed at identifying genetic risk factors for ovarian cancer in *BRCA1* mutation carriers through a genome wide association study in *BRCA1* mutation carriers. The overall intent was to complete a genome wide association study of *BRCA1* carriers, validate candidate risk modifiers, to assess the contribution of these modifiers to sporadic ovarian cancer and to develop risk prediction models.

Body

Aim 1: To conduct a genome-wide association scan in 1,000 *BRCA1* carriers with ovarian cancer and 1,000 age-matched unaffected *BRCA1* carriers.

As outlined in detail in our previous annual report, we recently conducted a GWAS of *BRCA1* mutation carriers diagnosed with ovarian cancer. In collaboration with Drs. Douglas Easton and Antonis Antoniou at the University of Cambridge, we evaluated associations with both breast and ovarian cancer using a retrospective likelihood model. For ovarian cancer, 10 SNPs exhibited associations of $p < 1 \times 10^{-5}$ and 37 had associations of $p < 1 \times 10^{-4}$. Interestingly, rs1339552 on chromosome 9 in BCN2 and rs7651446 from TIPARP on chromosome 3 found to exhibit genome wide associations with ovarian cancer in the general population also showed highly significant associations ($p = 1.9 \times 10^{-5}$ and $p = 1.7 \times 10^{-4}$, respectively) with ovarian cancer in *BRCA1* mutation carriers. These loci can be considered genetic risk factors for ovarian cancer in *BRCA1* mutation carriers. These efforts completed the proposed studies in Aim, which include Task 1-4.

Aim 2: To further evaluate observed associations between ovarian cancer risk and SNPs implicated in Aim 1 by genotyping 1,500 *BRCA1* ovarian cancer cases and 1,500 unaffected *BRCA1* carriers.

GWAS validation studies

In our previous annual report we described our involvement in the iCOGS study of 211,000 candidate SNPs, which included 35,000 candidate SNPs from the *BRCA1* GWAS including 6,000 from the *BRCA1* Ovarian Cancer GWAS. Genotyping data from the original GWAS and the iCOGS study were available from 9866 unaffected *BRCA1* mutation carriers and 1839 affected with ovarian cancer. A total of 62 SNPs in 17 regions were associated with ovarian cancer risk for *BRCA1* carriers at $P < 10^{-4}$. These included SNPs in the BNC2 9p22 and 3q25 loci previously associated with ovarian cancer risk in both the general population and *BRCA1* carriers. Associations ($P < 0.01$) with ovarian cancer risk were also observed for SNPs in three other known ovarian cancer susceptibility loci (8q24, 17q21, 19p13), but not 2q31. After excluding SNPs from known ovarian cancer susceptibility regions, there were 48 SNPs in 15 regions with $P = 5 \times 10^{-7}$ to 10^{-4} . Five SNPs from four of these loci were genotyped in additional stage 3 samples (2,204 unaffected, 442 with ovarian cancer). In the combined stage 1-3 analyses, SNPs rs17631303 and rs183211 ($r^2 = 0.68$) on chromosome 17q21.31 had P-values for association of 1×10^{-8} and 3×10^{-8} respectively, and rs4691139 at 4q32.3 had a P-value of 3.4×10^{-8} . None of these

SNPs were associated with breast cancer in *BRCA1* mutation carriers. Imputation using data from the 1000 Genomes Project, identified several SNPs in 17q21.31 with stronger associations than the most significant genotyped SNP in the combined *BRCA1/2* analysis (rs169201, $P=6.24 \times 10^{-11}$). The most significant SNP (rs140338099 (17-44034340), $P=3 \times 10^{-12}$) located in *MAPT*, was highly correlated ($r^2=0.78$) with rs169201 in *NSF*. This locus appears to be distinct from a previously identified sporadic ovarian cancer susceptibility locus located >1Mb distal on 17q21 (spanning 43.3-44.3Mb, build 36.3). Analysis of associations with variants identified through 1000 Genomes Project based imputation of the Stage 1 and 2 samples, also revealed 19 SNPs with stronger evidence of association ($P=5.4 \times 10^{-7}$ to 1.1×10^{-6}) than rs4691139 on 4q32.3. All were highly correlated (pairwise $r^2 > 0.89$) and the most significant (rs4588418) had $r^2=0.97$ with rs4691139. No association was found between rs4691139 and ovarian cancer risk in the general population based on data by the Ovarian Cancer Association Consortium (OCAC) in 18,174 cases and 26,134 controls (Odds Ratio=1.00, 95%CI:0.97-1.04, $P=0.76$). Based on these efforts we have completed Tasks 5 to 9 from Aim 2.

Aim 3: To evaluate risk modifiers from the *BRCA1* breast cancer GWAS and risk factors from sporadic ovarian cancer GWAS as modifiers of ovarian cancer in *BRCA1* carriers.

To improve statistical power to identify ovarian cancer risk loci for *BRCA1* mutation carriers, a meta-analysis of association test results from the *BRCA1* iCOGS (12,790 unaffected; 2,462 affected) and OCAC iCOGS (18,174 EOC cases; 26,134 controls) studies was conducted. Six new genome wide significant loci were identified through this process including: rs3820282 in *WNT4* ($p=2.0 \times 10^{-8}$); rs12039431 *RSPO1* ($p=1.44 \times 10^{-11}$); rs17329882 in *SYNPO2* ($p=1.95 \times 10^{-8}$); rs115344852 in *GPX5* ($p=3.15 \times 10^{-8}$); 136138765 in *ABO* ($p=1.95 \times 10^{-8}$); rs8044477 in *GOT2* ($p=1.0 \times 10^{-8}$). All were novel associations that also showed significance ($p < 0.05$) in *BRCA1* carriers alone. This effort substantially increased the number of risk loci for ovarian cancer in *BRCA1* mutation carriers. We previously reported that variants from the 19p13.1 locus were associated with ovarian cancer risk in a genotyping study of 12,599 *BRCA1* and 7,132 *BRCA2* mutation carriers, which included 1,465 *BRCA1* mutation carriers and 453 *BRCA2* mutation carriers with ovarian cancer. The rs67397200 SNP at 19p13.1 was strongly associated with ovarian cancer risk in *BRCA1* (HR=1.16; 95%CI 1.05-1.29; $p=3.8 \times 10^{-4}$) and *BRCA2* (HR=1.30; 95%CI 1.10-1.52; $p=1.8 \times 10^{-3}$) mutation carriers. This SNP and others in this locus were also associated with breast cancer risk in *BRCA1* mutation carriers. To fine map the 19p13.1 locus in an effort to identify the causative variants in this region a meta-analysis of results from the OCAC and *BRCA1* ovarian cancer studies and the BCAC and *BRCA1* breast cancer studies using 1000 Genomes imputed SNP was conducted. Results show that SNPs in the *ANKLE1* locus on 19p13.1 appear to drive the association with breast and ovarian cancer (Table 1).

Table 1 Most significant associations for SNPs in a meta-analysis of breast and ovarian cancer studies

MarkerName	P.value	LOCATION	Direction	bcac_snpname	position	bcac_pval	brca1_pval	ocac_pval
17390291_T_C	1.55E-26	BABAM1	--	rs4808075	17390291	4.42E-13	4.77E-15	9.17E-20
17390917_G_C	8.34E-23	ANKLE1	--	rs4609972	17390917	4.42E-10	1.10E-14	5.93E-14
17391328_G_A	2.70E-26	ANKLE1	++	rs10419397	17391328	6.57E-13	5.55E-15	1.29E-19
17392894_G_A	1.04E-23	ANKLE1	--	rs8100241	17392894	1.28E-10	5.11E-15	8.66E-14
17393530_T_A	4.02E-23	ANKLE1	--	rs8108174	17393530	2.15E-10	1.23E-14	7.16E-14
17393925_C_A	5.26E-27	ANKLE1	++	rs56069439	17393925	2.22E-13	3.33E-15	1.94E-19
17394124_T_G	9.52E-24	ANKLE1	++	rs2363956	17394124	1.31E-10	4.44E-15	5.75E-14
17395401_C_T	5.59E-27	ANKLE1	++	rs4808076	17395401	2.90E-13	2.55E-15	3.72E-19
17396942_C_T	3.48E-23	ANKLE1	--	rs748850	17396942	1.84E-10	1.27E-14	5.47E-14
17398085_C_A	6.07E-27	ANKLE1	++	rs111961716	17398085	2.63E-13	3.22E-15	6.97E-19
17399625_T_C	2.12E-23		++	rs11668840	17399625	1.86E-10	6.99E-15	9.40E-14
17400765_T_C	4.22E-27		--	rs113299211	17400765	2.40E-13	2.33E-15	8.13E-19
17401521_C_T	7.66E-23		--	rs12974508	17401521	1.40E-10	4.30E-14	1.23E-13
17401859_G_A	7.31E-28		++	c19_pos17262859	17401859	1.27E-13	7.77E-16	1.14E-18
17404072_T_A	2.81E-27	ABHD8	++	rs55924783	17404072	1.61E-13	2.44E-15	1.35E-18
17406167_C_T	4.55E-27	ABHD8	++	rs28473003	17406167	2.80E-13	2.11E-15	3.43E-18
17407695_G_T	2.06E-26	ABHD8	++	rs13343778	17407695	3.92E-13	7.44E-15	3.18E-18
17409380_C_T	4.08E-22	ABHD8	--	rs12982058	17409380	8.63E-10	2.90E-14	5.14E-13
17409671_C_T	2.56E-25	ABHD8	++	rs10424198	17409671	1.18E-12	3.13E-14	3.85E-18

These studies complete Task 10. Additional studies addressing Tasks 11-13 are underway as outlined in a recently approved no cost extension for this award.

Key Research Accomplishments

- Completed a validation study of candidate ovarian cancer risk modifiers for *BRCA1* mutation carriers.
- Verified three known ovarian cancer risk factors as ovarian cancer risk modifiers for *BRCA1* mutation carriers
- Identified novel ovarian cancer risk modifier loci for *BRCA1* mutation carriers on chromosome 4q32 and 17q21.
- Identified six new ovarian cancer susceptibility loci in a meta-analysis of *BRCA1* and sporadic ovarian cancer studies.

Reportable Outcomes

1. Antoniou AC, Kuchenbaecker KB, Soucy P, Beesley J, Chen X, McGuffog L, Lee A, Barrowdale D, Healey S, Sinilnikova OM, Caligo MA, Loman N, Harbst K, Lindblom A, Arver B, Rosenquist R, Karlsson P, Nathanson K, Domchek S, Rebbeck T, Jakubowska A, Lubinski J, Jaworska K, Durda K, Zlowocka-Perlowska E, Osorio A, Duran M, Andres R, Benitez J, Hamann U, Hogervorst FB, A van O T, Verhoef S, Meijers-Heijboer HE, Wijnen J, Gomez Garcia EB, Ligtenberg MJ, Kriege M, Collee JM, Ausems MG, Oosterwijk JC, Peock S, Frost D, Ellis SD, Platte R, Fineberg E, Evans DG, Lalloo F, Jacobs C, Eeles R, Adlard J, Davidson R, Cole T, Cook J, Paterson J, Douglas F, Brewer C, Hodgson S, Morrison PJ, Walker L, Rogers MT, Donaldson A, Dorkins H, Godwin AK, Bove B, Stoppa-Lyonnet D, Houdayer C, Buecher B, de Pauw A, Mazoyer S, Calender A, Leone M, Bressac-de Paillerets B, Caron O, Sobol H, Frenay M, Prieur F, Fert Ferrer S, Mortemousque I, Buys S, Daly M, Miron A, Terry MB, Hopper JL, John EM, Southey M, Goldgar D, Singer CF, Fink-Retter A, Tea MK, Geschwantler Kaulich D, Hansen TV, Nielsen FC, Barkardottir RB, Gaudet M, Kirchhoff T, Joseph V, Dutra-Clarke A, Offit K, Piedmonte M, Kirk J, Cohn D, Hurteau J, Byron J, Fiorica J, Toland AE, Montagna M, Olini C, Ilyanov E, Isaacs C, Tihomirova L, Blanco I, Lazaro C, Teule A, Del Valle J, Gayther SA, Odunsi K, Gross J, Karlan BY, Olah E, Teo SH, Ganz PA, Beattie MS, Dorfling CM, Jansen van Rensburg E, Diez O, Kwong A, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Ditsch N, Arnold N, Heidemann S, Niederacher D, Preisler-Adams S, Gadzicki D, Varon-Mateeva R, Deissler H, Gehrig A, Sutter C, Kast K, Fiebig B, Schafer D, Caldes T, de la Hoya M, Nevanlinna H, Muranen TA, Lesperance B, Spurdle AB, Neuhausen SL, Ding YC, Wang X, Fredericksen Z, Pankratz VS, Lindor NM, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Bonanni B, Bernard L, Dolcetti R, Papi L, Ottini L, Radice P, Greene MH, Loud JT, Andrulis IL, Ozelik H, Mulligan AM, Glendon G, Thomassen M, Gerdes AM, Jensen UB, Skytte AB, Kruse TA, Chenevix-Trench G, **Couch FJ**, Simard J, Easton DF, Swedish Breast Cancer Study, HEBON, EMBRACE, GEMO Collaborators, kConFab Investigators. Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for *BRCA1* and/or *BRCA2* mutation carriers. *Breast Cancer Res.* 14(1):R33, 2012. PMC3496151. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3319317/>
2. Permuth-Wey J, Lawrenson K, Shen HC, Velkova A, Tyrer JP, Chen Z, Lin HY, Ann Chen Y, Tsai YY, Qu X, Ramus SJ, Karevan R, Lee J, Lee N, Larson MC, Aben KK, Anton-Culver H, Antonenkova N, Antoniou AC, Armasu SM; stralian Cancer Study; stralian Ovarian Cancer Study, Bacot F, Baglietto L, Bandera EV, Barnholtz-Sloan J, Beckmann MW, Birrer MJ, Bloom G, Bogdanova N, Brinton LA, Brooks-Wilson A, Brown R, Butzow R, Cai Q, Campbell I, Chang-Claude J, Chanock S, Chenevix-Trench G, Cheng JQ, Cicek MS, Coetzee GA; Consortium of Investigators of Modifiers of *BRCA1/2*, Cook LS, Couch FJ, Cramer DW, Cunningham JM, Dansonka-Mieszkowska A, Despierre E, Doherty JA, Dörk T, du Bois A, Dürst M, Easton DF, Eccles D, Edwards R, Ekici AB, Fasching PA, Fenstermacher DA, Flanagan JM, Garcia-Closas M, Gentry-Maharaj A, Giles GG, Glasspool RM, Gonzalez-Bosquet J, Goodman MT, Gore M, Górski B, Gronwald J, Hall P, Halle MK, Harter P, Heitz F, Hillemanns P, Hoatlin M, Høgdall CK,

Høgdall E, Hosono S, Jakubowska A, Jensen A, Jim H, Kalli KR, Karlan BY, Kaye SB, Kelemen LE, Kiemeny LA, Kikkawa F, Konecny GE, Krakstad C, Krüger Kjaer S, Kupryjanczyk J, Lambrechts D, Lambrechts S, Lancaster JM, Le ND, Leminen A, Levine DA, Liang D, Kiong Lim B, Lin J, Lissowska J, Lu KH, Lubiński J, Lurie G, Massuger LF, Matsuo K, McGuire V, McLaughlin JR, Menon U, Modugno F, Moysich KB, Nakanishi T, Narod SA, Nedergaard L, Ness RB, Nevanlinna H, Nickels S, Noushmehr H, Odunsi K, Olson SH, Orlow I, Paul J, Pearce CL, Pejovic T, Peltari LM, Pike MC, Poole EM, Raska P, Renner SP, Risch HA, Rodriguez-Rodriguez L, Anne Rossing M, Rudolph A, Runnebaum IB, Rzepecka IK, Salvesen HB, Schwaab I, Severi G, Shridhar V, Shu XO, Shvetsov YB, Sieh W, Song H, Southey MC, Spiewankiewicz B, Stram D, Sutphen R, Teo SH, Terry KL, Tessier DC, Thompson PJ, Tworoger SS, van Altena AM, Vergote I, Vierkant RA, Vincent D, Vitonis AF, Wang-Gohrke S, Palmieri Weber R, Wentzensen N, Whittemore AS, Wik E, Wilkens LR, Winterhoff B, Ling Woo Y, Wu AH, Xiang YB, Yang HP, Zheng W, Ziogas A, Zulkifli F, Phelan CM, Iversen E, Schildkraut JM, Berchuck A, Fridley BL, Goode EL, Pharoah PD, Monteiro AN, Sellers TA, Gayther SA. Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. *Nat Commun.* 4:1627, 2013. PMC3709460. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3709460/>

3. Couch FJ, Wang X, McGuffog L, Lee A, Olswold C, Kuchenbaecker KB, Soucy P, Fredericksen Z, Barrowdale D, Dennis J, Gaudet MM, Dicks E, Kosel M, Healey S, Sinilnikova OM, Lee A, Bacot F, Vincent D, Hogervorst FB, Peock S, Stoppa-Lyonnet D, Jakubowska A, Investigators K, Radice P, Schmutzler RK; SWE-BRCA, Domchek SM, Piedmonte M, Singer CF, Friedman E, Thomassen M; Ontario Cancer Genetics Network, Hansen TV, Neuhausen SL, Szabo CI, Blanco I, Greene MH, Karlan BY, Garber J, Phelan CM, Weitzel JN, Montagna M, Olah E, Andrulis IL, Godwin AK, Yannoukakos D, Goldgar DE, Caldes T, Nevanlinna H, Osorio A, Terry MB, Daly MB, van Rensburg EJ, Hamann U, Ramus SJ, Ewart Toland A, Caligo MA, Olopade OI, Tung N, Claes K, Beattie MS, Southey MC, Imyanitov EN, Tischkowitz M, Janavicius R, John EM, Kwong A, Diez O, Balmaña J, Barkardottir RB, Arun BK, Rennert G, Teo SH, Ganz PA, Campbell I, van der Hout AH, van Deurzen CH, Seynaeve C, Gómez Garcia EB, van Leeuwen FE, Meijers-Heijboer HE, Gille JJ, Ausems MG, Blok MJ, Ligtenberg MJ, Rookus MA, Devilee P, Verhoef S, van Os TA, Wijnen JT; HEBON; EMBRACE, Frost D, Ellis S, Fineberg E, Platte R, Evans DG, Izatt L, Eeles RA, Adlard J, Eccles DM, Cook J, Brewer C, Douglas F, Hodgson S, Morrison PJ, Side LE, Donaldson A, Houghton C, Rogers MT, Dorkins H, Eason J, Gregory H, McCann E, Murray A, Calender A, Hardouin A, Berthet P, Delnatte C, Nogues C, Lasset C, Houdayer C, Leroux D, Rouleau E, Prieur F, Damiola F, Sobol H, Coupier I, Venat-Bouvet L, Castera L, Gauthier-Villars M, Léoné M, Pujol P, Mazoyer S, Bignon YJ; GEMO Study Collaborators, Złowocka-Perłowska E, Gronwald J, Lubinski J, Durda K, Jaworska K, Huzarski T, Spurdle AB, Viel A, Peissel B, Bonanni B, Melloni G, Ottini L, Papi L, Varesco L, Tibiletti MG, Peterlongo P, Volorio S, Manoukian S, Pensotti V, Arnold N, Engel C, Deissler H, Gadzicki D, Gehrig A, Kast K, Rhiem K, Meindl A, Niederacher D, Ditsch N, Plendl H, Preisler-Adams S, Engert S, Sutter C, Varon-Mateeva R, Wappenschmidt B, Weber BH, Arver B, Stenmark-Askmal M, Loman N, Rosenquist R, Einbeigi Z, Nathanson KL, Rebbeck TR, Blank SV, Cohn DE, Rodriguez GC, Small L, Friedlander M, Bae-Jump VL, Fink-Retter A, Rappaport C, Gschwantler-Kaulich D, Pfeiler G, Tea MK, Lindor NM, Kaufman B, Shimon Paluch S, Laitman Y, Skytte AB, Gerdes AM, Pedersen IS, Moeller ST, Kruse TA, Jensen UB, Vijai J, Sarrel K, Robson M, Kauff N, Mulligan AM, Glendon G, Ozelik H, Ejlersen B, Nielsen FC, Jønson L, Andersen MK, Ding YC, Steele L, Foretova L, Teulé A, Lazaro C, Brunet J, Pujana MA, Mai PL, Loud JT, Walsh C, Lester J, Orsulic S, Narod SA, Herzog J, Sand SR, Tognazzo S, Agata S, Vaszko T, Weaver J, Stavropoulou AV, Buys SS, Romero A, de la Hoya M, Aittomäki K, Muranen TA, Duran M, Chung WK, Lasa A, Dorfling CM, Miron A; BCFR, Benitez J, Senter L, Huo D, Chan SB, Sokolenko AP, Chiquette J, Tihomirova L, Friebel TM, Agnarsson BA, Lu KH, Lejbkiewicz F, James PA, Hall P, Dunning AM, Tessier D, Cunningham J, Slager SL, Wang C, Hart S, Stevens K, Simard J, Pastinen T, Pankratz VS, Offit K, Easton DF, Chenevix-Trench G, Antoniou AC; CIMBA. Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. *PLoS Genet.* 9(3):e1003212, 2013. PMC3609646. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3609646/>

4. Gaudet MM, Kuchenbaecker KB, Vijai J, Klein RJ, Kirchhoff T, McGuffog L, Barrowdale D, Dunning AM, Lee A, Dennis J, Healey S, Dicks E, Soucy P, Sinilnikova OM, Pankratz VS, Wang X, Eldridge RC, Tessier DC, Vincent D, Bacot F, Hogervorst FB, Peock S, Stoppa-Lyonnet D; KConFab Investigators, Peterlongo P, Schmutzler RK, Nathanson KL, Piedmonte M, Singer CF, Thomassen M; Ontario Cancer Genetics Network, Hansen TV, Neuhausen SL, Blanco I, Greene MH, Garber J, Weitzel JN, Andrulis IL, Goldgar DE, D'Andrea E, Caldes T, Nevanlinna H, Osorio A, van Rensburg EJ, Arason A, Rennert G, van den Ouweland AM, van der Hout AH, Kets CM, Aalfs CM, Wijnen JT, Ausems MG; HEBON; EMBRACE, Frost D, Ellis S, Fineberg E, Platte R, Evans DG, Jacobs C, Adlard J, Tischkowitz M, Porteous ME, Damiola F; GEMO Study Collaborators, Golmard L, Barjhoux L, Longy M, Belotti M, Ferrer SF, Mazoyer S, Spurdle AB, Manoukian S, Barile M, Genuardi M, Arnold N, Meindl A, Sutter C, Wappenschmidt B, Domchek SM, Pfeiler G, Friedman E, Jensen UB, Robson M, Shah S, Lazaro C, Mai PL, Benitez J, Southey MC, Schmidt MK, Fasching PA, Peto J, Humphreys MK, Wang Q, Michailidou K, Sawyer EJ, Burwinkel B, Guénel P, Bojesen SE, Milne RL, Brenner H, Lochmann M; GENICA Network, Aittomäki K, Dörk T, Margolin S, Mannermaa A, Lambrechts D, Chang-Claude J, Radice P, Giles GG, Haiman CA, Winqvist R, Devilee P, García-Closas M, Schoof N, Hooning MJ, Cox A, Pharoah PD, Jakubowska A, Orr N, González-Neira A, Pita G, Alonso MR, Hall P, Couch FJ, Simard J, Altshuler D, Easton DF, Chenevix-Trench G, Antoniou AC, Offit K. Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk. *PLoS Genet.* 9(3):e1003173, 2013: PMC3609647. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3609647/>
5. Bojesen SE, Pooley KA, Johnatty SE, Beesley J, Michailidou K, Tyrer JP, Edwards SL, Pickett HA, Shen HC, Smart CE, Hillman KM, Mai PL, Lawrenson K, Stutz MD, Lu Y, Karevan R, Woods N, Johnston RL, French JD, Chen X, Weischer M, Nielsen SF, Maranian MJ, Ghoussaini M, Ahmed S, Baynes C, Bolla MK, Wang Q, Dennis J, McGuffog L, Barrowdale D, Lee A, Healey S, Lush M, Tessier DC, Vincent D, Bacot F; Australian Cancer Study; Australian Ovarian Cancer Study; Kathleen Cuninghame Foundation Consortium for Research into Familial Breast Cancer (kConFab); Gene Environment Interaction and Breast Cancer (GENICA); Swedish Breast Cancer Study (SWE-BRCA); Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON); Epidemiological study of BRCA1 & BRCA2 Mutation Carriers (EMBRACE); Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers (GEMO), Vergote I, Lambrechts S, Despiere E, Risch HA, González-Neira A, Rossing MA, Pita G, Doherty JA, Alvarez N, Larson MC, Fridley BL, Schoof N, Chang-Claude J, Cicek MS, Peto J, Kalli KR, Broeks A, Armasu SM, Schmidt MK, Braaf LM, Winterhoff B, Nevanlinna H, Konecny GE, Lambrechts D, Rogmann L, Guénel P, Teoman A, Milne RL, Garcia JJ, Cox A, Shridhar V, Burwinkel B, Marme F, Hein R, Sawyer EJ, Haiman CA, Wang-Gohrke S, Andrulis IL, Moysich KB, Hopper JL, Odunsi K, Lindblom A, Giles GG, Brenner H, Simard J, Lurie G, Fasching PA, Carney ME, Radice P, Wilkens LR, Swerdlow A, Goodman MT, Brauch H, Garcia-Closas M, Hillemanns P, Winqvist R, Dürst M, Devilee P, Runnebaum I, Jakubowska A, Lubinski J, Mannermaa A, Butzow R, Bogdanova NV, Dörk T, Peltari LM, Zheng W, Leminen A, Anton-Culver H, Bunker CH, Kristensen V, Ness RB, Muir K, Edwards R, Meindl A, Heitz F, Matsuo K, du Bois A, Wu AH, Harter P, Teo SH, Schwaab I, Shu XO, Blot W, Hosono S, Kang D, Nakanishi T, Hartman M, Yatabe Y, Hamann U, Karlan BY, Sangrajrang S, Kjaer SK, Gaborieau V, Jensen A, Eccles D, Høgdall E, Shen CY, Brown J, Woo YL, Shah M, Azmi MA, Luben R, Omar SZ, Czene K, Vierkant RA, Nordestgaard BG, Flyger H, Vachon C, Olson JE, Wang X, Levine DA, Rudolph A, Weber RP, Flesch-Janys D, Iversen E, Nickels S, Schildkraut JM, Silva Idos S, Cramer DW, Gibson L, Terry KL, Fletcher O, Vitonis AF, van der Schoot CE, Poole EM, Hogervorst FB, Tworoger SS, Liu J, Bandera EV, Li J, Olson SH, Humphreys K, Orlov I, Blomqvist C, Rodriguez-Rodriguez L, Aittomäki K, Salvesen HB, Muranen TA, Wik E, Brouwers B, Krakstad C, Wauters E, Halle MK, Wildiers H, Kiemeny LA, Mulot C, Aben KK, Laurent-Puig P, Altena AM, Truong T, Massuger LF, Benitez J, Pejovic T, Perez JI, Hoatlin M, Zamora MP, Cook LS, Balasubramanian SP, Kelemen LE, Schneeweiss A, Le ND, Sohn C, Brooks-Wilson A, Tomlinson I, Kerin MJ, Miller N, Cybulski C, Henderson BE, Menkiszak J, Schumacher F, Wentzensen N, Le Marchand L, Yang HP, Mulligan AM, Glendon G, Engelholm SA, Knight JA, Høgdall CK, Apicella C, Gore M, Tsimiklis H, Song H, Southey MC, Jager A, den Ouweland AM, Brown R, Martens JW, Flanagan JM, Kriege M, Paul J, Margolin S, Siddiqui N, Severi G, Whittemore AS, Baglietto L, McGuire V, Stegmaier C, Sieh W, Müller H, Arndt V, Labrèche F, Gao YT, Goldberg MS, Yang G, Dumont M, McLaughlin JR,

Hartmann A, Ekici AB, Beckmann MW, Phelan CM, Lux MP, Permuth-Wey J, Peissel B, Sellers TA, Ficarazzi F, Barile M, Ziogas A, Ashworth A, Gentry-Maharaj A, Jones M, Ramus SJ, Orr N, Menon U, Pearce CL, Brüning T, Pike MC, Ko YD, Lissowska J, Figueroa J, Kupryjanczyk J, Chanock SJ, Dansonka-Mieszkowska A, Jukkola-Vuorinen A, Rzepecka IK, Pylkäs K, Bidzinski M, Kauppila S, Hollestelle A, Seynaeve C, Tollenaar RA, Durda K, Jaworska K, Hartikainen JM, Kosma VM, Kataja V, Anttonen NN, Long J, Shrubsole M, Deming-Halverson S, Lophatananon A, Siriwanarangsang P, Stewart-Brown S, Ditsch N, Lichtner P, Schmutzler RK, Ito H, Iwata H, Tajima K, Tseng CC, Stram DO, van den Berg D, Yip CH, Ikram MK, Teh YC, Cai H, Lu W, Signorello LB, Cai Q, Noh DY, Yoo KY, Miao H, Iau PT, Teo YY, McKay J, Shapiro C, Ademuyiwa F, Fountzilas G, Hsiung CN, Yu JC, Hou MF, Healey CS, Luccarini C, Peock S, Stoppa-Lyonnet D, Peterlongo P, Rebbeck TR, Piedmonte M, Singer CF, Friedman E, Thomassen M, Offit K, Hansen TV, Neuhausen SL, Szabo CI, Blanco I, Garber J, Narod SA, Weitzel JN, Montagna M, Olah E, Godwin AK, Yannoukakis D, Goldgar DE, Caldes T, Imyanitov EN, Tihomirova L, Arun BK, Campbell I, Mensenkamp AR, van Asperen CJ, van Roozendaal KE, Meijers-Heijboer H, Collée JM, Oosterwijk JC, Hooning MJ, Rookus MA, van der Luijt RB, Os TA, Evans DG, Frost D, Fineberg E, Barwell J, Walker L, Kennedy MJ, Platte R, Davidson R, Ellis SD, Cole T, Bressac-de Paillerets B, Buecher B, Damiola F, Faivre L, Frenay M, Sinilnikova OM, Caron O, Giraud S, Mazoyer S, Bonadona V, Caux-Moncoutier V, Toloczko-Grabarek A, Gronwald J, Byrski T, Spurdle AB, Bonanni B, Zaffaroni D, Giannini G, Bernard L, Dolcetti R, Manoukian S, Arnold N, Engel C, Deissler H, Rhiem K, Niederacher D, Plendl H, Sutter C, Wappenschmidt B, Borg A, Melin B, Rantala J, Soller M, Nathanson KL, Domchek SM, Rodriguez GC, Salani R, Kaulich DG, Tea MK, Paluch SS, Laitman Y, Skytte AB, Kruse TA, Jensen UB, Robson M, Gerdes AM, Ejlersen B, Foretova L, Savage SA, Lester J, Soucy P, Kuchenbaecker KB, Olswold C, Cunningham JM, Slager S, Pankratz VS, Dicks E, Lakhani SR, Couch FJ, Hall P, Monteiro AN, Gayther SA, Pharoah PD, Reddel RR, Goode EL, Greene MH, Easton DF, Berchuck A, Antoniou AC, Chenevix-Trench G, Dunning AM. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. *Nat Genet.* 45(4):371-84, 2013. PMC3670748. <http://www.nature.com/ng/journal/v45/n4/full/ng.2566.html>

Conclusion

In summary, we have completed the discovery and validation phases of an ovarian cancer GWAS for *BRCA1* mutation carriers. We verified that variants from five loci that have been associated with risk of ovarian cancer in the general population are risk modifiers of ovarian cancer for *BRCA1* mutation carriers. In addition, two novel loci at 4q32 and 17q21 were associated with ovarian cancer risk in *BRCA1* carriers. Of these the 4q32 locus was not associated with ovarian cancer in *BRCA2* mutation carriers or the general population. Thus, specific modifiers of ovarian cancer risk exist for this population. Six novel ovarian cancer risk loci were also observed by combining results from *BRCA1* and sporadic ovarian cancer studies. The 13 risk modifiers of ovarian cancer risk are useful for predicting differences in individual ovarian cancer risk among *BRCA1* mutation carriers. Ongoing genotyping of other candidate variants are expected to be useful for improved risk assessment of ovarian and breast cancer risk for *BRCA1* and perhaps *BRCA2* mutation carriers.